That similar data have also been reported for tumor‐bearing mice undergoing dual TIM‐3/CTLA‐4 blockade178 and for TIL treated with other combinations of checkpoint inhibitors185 underscores the potential utility of combinatorial approaches to checkpoint blockade therapy as a means of eliciting robust antitumor immunity. The gene discussed is CTLA4; the disease is neoplasm.